CD55 (DAF), Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-CD55 (DAF), Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | CD55 (DAF), Human |
| Clone | JS11 |
| Host Species | Mouse |
| Reactive Species | human |
| Isotype | IgG1κ |
| Format | fluorescein (FITC) conjugate |
| Size | 100 tests in 200 µL |
| Concentration | 1:50 |
| Applications | Flow cytometry, MICS (MACSima Imaging Cyclic Staining), Immunofluorescence, Immunohistochemistry |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | CD55 (DAF) Antibody, anti-human, FITC. Clone JS11 recognizes the CD55 antigen, a 70 kDa glycosylphosphatidylinositol-anchored single chain glycoprotein, which is also known as complement decay-accelerating factor (DAF). CD55 is broadly distributed among hematopoietic and non-hematopoietic cells. It is expressed on the plasma membranes of all cell types that are in intimate contact with serum and on the surfaces of epithelial cells lining the extracellular compartments. Variants of the molecule are present in body fluids and in extracellular matrix. CD55 plays multiple physiologic roles including tissue protection from the cytotoxic complement injury, anti-inflammatory function owing to its anti-adherence properties which enhance transmigration of monocytes and macrophages and reduce tissue injury. CD55 plays an essential role during pregnancy and is involved in the protection of the semiallogeneic fetus and in preventing uncontrolled infiltration by white cells. It is exploited in multiple pathologic conditions by pathogens and viruses in chronic tissue infection processes. |
| Immunogen | n/a |
| Other Names | CR, CROM, DAF, TC |
| Gene, Accession # | n/a |
| Catalog # | 130-126-382 |
| Price | $265 |
| Order / More Info | CD55 (DAF), Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Caras, I. W. et al. (1987) Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins. Nature 325 (6104): 545-549. | Nowicki, B. et al. (2013) DAF as a therapeutic target for steroid hormones: implications for host-pathogen interactions. Adv. Exp. Med. Biol. 734: 83-96. | Osuka, F. et al. (2006) Molecular cloning and characterization of novel splicing variants of human decay-accelerating factor. Genomics 88 (3): 316-322. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG